Loading...
XNAS
BGMS
Market cap2mUSD
Jul 09, Last price  
0.92USD
1D
5.72%
1Q
-8.79%
Jan 2017
-82.61%
Name

Cyclacel Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:BGMS chart
P/E
—
P/S
2.69
EPS
—
Div Yield, %
—
Shrs. gr., 5y
364.64%
Rev. gr., 5y
22.87%
Revenues
747k
+1,637.21%
387,000129,000877,000911,000686,000699,00069,0001,084,0001,734,0001,944,000843,0000150,0000000420,00043,000747,000
Net income
-3m
L-73.26%
-29,258,000-24,053,000-40,386,000-19,570,000-16,021,000-15,243,000-13,186,000-10,153,000-19,387,000-14,342,000-11,791,000-7,470,000-7,288,000-7,830,000-8,445,000-18,457,000-21,198,000-22,555,000-11,212,000-2,998,000
CFO
-5m
L-40.30%
-20,172,000-23,140,000-29,905,000-15,193,000-16,044,000-13,977,000-12,043,000-18,199,000-18,702,000-14,460,000-10,079,000-7,480,000-6,701,000-9,447,000-7,934,000-18,540,000-20,827,000-16,112,000-7,990,000-4,770,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitters Sdn. Bhd., a Malaysian firm known for its fire safety products and services. BGMS is committed to driving progress in biopharmaceutical research and developing cutting-edge fire safety solutions, striving to deliver enduring value to its investors.
URL
https://cyclacel.com/
IPO date
Jan 01, 1996
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT